Global Infusion Pump Market By Type (Volumetric Pumps, Enteral Pumps, Syringe Pumps, and Other), By Disease Indication (Diabetes, Chemotherapy, Analgesia/Pain Management, and Other Disease Indications), and End-User (Hospitals & Clinics, Home Care Settings, Ambulatory Care Settings, and Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032.

Report Overview

The Global Infusion Pump Market size is expected to be worth around USD 22.6 Billion by 2032 from USD 12.1 Billion in 2022, growing at a CAGR of 6.6 % during the forecast period from 2023 to 2032.

Hormones, medications, and nutritional fluids are infused into the circulatory system through veins using intravenous infusion pumps in controlled amounts. IV infusion pumps are frequently used in clinical settings like nursing homes, hospitals, and homes. Using built-in software, the pump’s duration and rate of fluid delivery are programmed by a trained operator. Nutrients, chemotherapy drugs, antibiotics, hormones, and painkillers can all be delivered through intravenous infusion pumps.

The market is seeing significant growth after leading players like Insulet Corporation, Medtronic, and others introduced insulin pumps. Due to key factors like advancements in drug delivery technologies, the rising prevalence of chronic diseases, and the growing adoption of these techniques in emerging regions. A pump is a medical device that precisely administers nutrients and fluids to the patient. These are made with particular functions in mind, like insulin pumps that give insulin to people, enteral feeding pumps that give nutrients to people, and patient-controlled analgesia (PCA) pumps that give painkillers to people.

In addition, these pumps can deliver fluid through subcutaneous, intravenous, and arterial routes. To achieve therapeutic efficacy and precise fluid delivery, these pumps have been preferred to the manually driven flow control method.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Market Growth: The market is expanding due to the increasing number of people with chronic diseases.
• Technological Advancements: Ongoing advancements in drug delivery technologies are driving market growth.
• Market Size Increase: The market is expected to reach USD 22.6 billion by 2032.
• Starting Point: In 2022, the market was worth USD 12.1 billion.
• Growth Rate: It is growing at a Compound Annual Growth Rate (CAGR) of 6.6% from 2023 to 2032.
• What is an Infusion Pump?: A pump is a medical device used to give nutrients and medications to patients in precise amounts.
• Common Uses: These pumps are commonly used in hospitals, nursing homes, and homes.
• Programmed Delivery: Trained operators program the pump to deliver fluids at specific rates and durations using built-in software.
• Types of Fluids: Nutrients, antibiotics, chemotherapy drugs, painkillers, and hormones can all be delivered through these pumps.
• Product Segment: In 2022, the wearables segment accounted for 34% of revenue.
• Application Segment: Monitoring had the highest market share and is expected to continue growing from 2023 to 2032.
• End-User Segment: Hospitals and clinics held the largest share of the market.
• Regional Dominance: North America led the market in 2022, with a 39% share.
• Fastest-Growing Region: Asia-Pacific is expected to have the fastest Compound Annual Growth Rate (CAGR) from 2023 to 2032.
• Factors Driving Growth: The market is growing due to factors like the rising prevalence of chronic diseases and advancements in drug delivery technologies.

Type Analysis

Volumetric Infusion Pumps Dominated the Market.

The infusion pump market is divided into volumetric pumps, enteral pumps, syringe pumps, insulin pumps, implantable pumps, elastomeric pumps, and PCA pumps based on the products they are made of. In 2022, volumetric infusion pumps commanded the largest market share of 28.2% due to their capacity to deliver constant, precise quantities of fluid at very slow to high-speed rates.

As these pumps are equipped with advanced features like drug libraries, which assist in storing the amount of medicated fluid given to the patient, and its barcode technology, which assists in the verification of a patient’s identity and helps prevent drug administration errors, smart pumps with controlled IV medication and error-prevention software are increasingly being used in recent years.

However, insulin infusion pumps are anticipated to experience the highest CAGR over the forecast period. This is because, primarily due to changing lifestyles and urbanization, the global burden of diabetes and its complications has increased significantly over the past decade. In addition, due to its low incidence of infections and delivery system failure during treatment, this pump market is anticipated to flourish in the foreseeable future.

Disease Indication Analysis

The Diabetes Sector Accounted for the Majority of the Market Share.

Diabetes, chemotherapy, analgesia/pain management, gastroenterology, hematology, pediatrics/neonatology, and other disease indications are among the market segments. The diabetes market accounted for the majority of the infusion pump market share of 29%. During the forecast period, the sector is anticipated to expand at the highest CAGR.

Furthermore, due to the rising incidence of various cancers and the rise in new product launches in this field, the oncology sector is anticipated to experience significant growth. This pump is also used in pediatrics, hematology, anesthesia, blood transfusion, gastroenterology, and other fields.

End-User Analysis

The Hospitals Segment Will Dominate the Global Infusion Pump Market due to the Rise in Global Hospital Admissions.

Based on end-users, the Market has been segmented into Hospitals & clinics, ambulatory care settings, and others. Due to hospitals’ high purchasing power of the most expensive infusion devices, the readiness of trained staff to operate the pump, and the large number of patients who visit these facilities, the hospitals & clinics segment accounted for the largest market share.

However, the growing preference for site-of-care management to reduce costs and the adoption of ambulatory pumps are expected to drive growth in the home care settings segment at the highest CAGR over the forecast period. In addition, the rising demand for infusion systems in the homecare setting is likely to be supported by increasing government initiatives to reduce the overall healthcare costs associated with prolonged hospitalization.

Furthermore, the availability of qualified professionals to operate infusion pumps, the large number of patients treated at hospitals, and the strong financial capabilities of hospitals for purchasing high-priced infusion devices all contribute to the segment’s expansion.

Key Market Segments

Based on Type

• Volumetric Pumps
• Enteral Pumps
• Syringe Pumps
• Insulin Pumps
• Implantable Pumps
• Elastomeric Pumps
• PCA Pumps

Based on Disease Indication

• Diabetes
• Chemotherapy
• Analgesia/Pain Management
• Gastroenterology
• Hematology
• Pediatrics/Neonatology
• Other Disease Indications

Based on End-User

• Hospitals & Clinics
• Home Care Settings
• Ambulatory Care Settings
• Other End-Users

Drivers

Increasing Adoption of Infusion Pumps for the Chronic Diseases Boost the Growth of the Market.

The treatment of various diseases, including cancer, diabetes, iron poisoning, and thromboembolic disease, is made possible by infusion pumps, which is increasing the use of medical devices in the healthcare industry. Depending on the disease, the pump injects nutrients or drugs into the patient’s body. For instance, intravenous (IV) infusion pumps deliver chemotherapy formulations into the patient’s body during cancer treatment. In order to make the device safer and easier to use, the software manages the pumping mechanism, maintains the prescribed infusion rate, and controls the user interface.

For example, to maintain normal blood glucose levels, type-1 people with diabetes must inject insulin externally at regular intervals. Using automated infusion pumps eliminates the need for a medical assistant, resulting in lower patient costs and precise hormone injections at the prescribed interval and dosage.

Digital Technologies Leads to Drive the Market’s Growth.

With the help of digital technologies, surgical procedures can be carried out by devices with minimal human intervention. The Internet of Things (IoT) has also increased interoperability between various healthcare facilities, speeding up the treatment and diagnosis process. In addition, the most recent technological advancements, such as static code analysis, which is widely utilized for confirming the correctness of programming codes, are enhancing the treatment machinery.

The system on which the software is installed can also be thoroughly tested with the assistance of this technology. Other technologies, such as model-based software development, are frequently used to create safety models during manufacturing. These technologies are helpful for various generic infusion pump projects and increase the software’s security to guard against cyberattacks. This rising demand for infusion pumps is anticipated to drive revenue growth during the forecast period.

Restraints

Market Revenue Growth is Anticipated to be Hindered by Cybersecurity Flaws and Infusion Pump Defects that Result in Mass Recalls.

Errors in the use of infusion pumps can result in significant patient injury, adverse medical effects, or even death because they are primarily used to administer vital fluids like glucose and other nutrients, as well as high-risk formulations. Due to reports of deaths and injuries, the Becton Dickinson Alaris System infusion pumps will be subject to a Class I recall by the FDA.

Also, in the past, the FDA had to recall several infusion pumps because of problems like user interface problems, software problems, and mechanical and electrical problems. In addition, pre-programmed alarms, which are installed to indicate any technical issue, can malfunction due to software issues.

Several false reports result from alarm activation failing in the absence of a problem or the presence of a problem. In addition, throughout the past few years, the FDA has received several Medical Device Reports (MDRs) about irregular fluid flow continuity in syringe pumps.

These MDRs can lead to severe medical issues like anxiety due to the loss of a sedative dose, unstable blood pressure, therapy delays, and over- or under-infusion. These issues have been observed with syringe and infusion pumps operating at a low infusion rate, and it is anticipated that they will limit market revenue growth to some extent.

Trends

Expanding Work on Research and Development for the Introduction of Home Infusion Systems.

Research and development efforts to create home-based infusion products have increased due to the rising cost of hospital-based infusion therapies and the rising prevalence of chronic diseases. For instance, the rising number of people with cancer, diabetes, and neurological disorders has increased the demand for long-term care, particularly in residential settings.

In addition, new products aimed at home-based infusion therapies are being developed in response to the growing geriatric population requiring long-term care treatments. The market’s leading players are concentrating on specialty medicine on-site care management. For example, Ivenix, Inc. released the smart infusion pump named Epic to help patients avoid injuries caused by infusions.

Regional Analysis

North America Dominates the Global Infusion Pump Market During the Forecast Period.

With a share of 36% in 2022, North America dominated the infusion pump market, which is expected to continue throughout the forecast period. The infusion pump industry in this region has grown as a result of the rising number of surgical procedures, the rising prevalence of chronic diseases, well-developed and expanding R&D, and the rising adoption of advanced technologies.

Due to its robust healthcare system, high expenditures on medical R&D, and high disease prevalence, the US held the largest market share of the North American infusion market. In addition, the American lifestyle and stressful work environment are responsible for the high prevalence of diabetes in the country. The Centers for Disease Control and Prevention (CDC) estimates that 34.2 million Americans were diagnosed with diabetes in 2018, and this number is expected to rise.

Over the forecast period, a significant CAGR is anticipated in the Asia-Pacific market. Countries in Asia have a large population and a high rate of chronic diseases like heart disease, diabetes, and cancer. Additionally, these nations are well-liked for the low cost of surgeries and treatments, making them a preferred market for medical tourism.

Emerging economies in Asia, including India, China, and Japan, have well-developed infrastructure and healthcare facilities. The intravenous infusion industry is poised to flourish as a result of factors such as the adoption of advanced technology, the low cost of treatments, a high disease burden, and significant government reform.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Medtronic Announced the Launch of Efficio Software for the Management of Targeted Drug Delivery. Also, Baxter International Launched SPECTRUM IQ to Improve the Efficiency of Drug Delivery.

For improved healthcare services, market players strategically utilize drivers like automation, standardized dosing, a technological shift, and widespread adoption of advanced healthcare technology. Furthermore, significant players frequently choose to expand geographically to maintain market share; and broaden their product range by implementing strategies like mergers, acquisitions, and new product launches.

A few key companies in the market are ICU Medical, Inc., Micrel Medical Devices SA, Dickinson and Company, Eitan Medical, Zyno Medical LLC, Baxter International Inc., Avanos Medical, Inc., Shenzhen MedRena Biotech Co., CareFusion Corporation, CODAN Medizinische Geräte GmbH & Co KG, Ypsomed Holding AG, Nipro Corporation, InfuTronix Solutions LLC, Bio-Medical Electronics Co., Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Fresenius Kabi Oncology Limited, Smiths Medical and other prominent players responsible for market growth.

The shift in automation, technology, standardized dosing, and widespread adoption of advanced healthcare technology for improved healthcare services is one of the primary factors driving competitiveness among market players. Additionally, major players are expanding geographically to maintain market share; and broaden their product range by implementing strategies like mergers, acquisitions, and new product launches.

For instance, in January 2020, Medtronic announced the availability of the targeted drug delivery management software Efficio for SynchroMed II. Baxter International also introduced SpectrumIQ, an electronic medical record-integrated infusion pump technology, and DeviceVue, an asset-tracking software to boost drug delivery efficiency.

Listed below are some of the most prominent global infusion pump market players.

Market Key Players

• Baxter International, Inc.
• B. Braun Melsungen AG
• Medtronic
• Becton Dickinson and Company
• Insulet Corporation
• Fresenius Kabi AG
• Roche Diagnostics
• InfuTronix Solutions LLC
• Other Key Players.

Key Industry developments

• In August 2022- The USFDA approval for the new Novum IQ Syringe Infusion Pump (SYR) was received by Baxter International. The SYR possesses Dose IQ Safety Software.
• In July 2022- The infusion set developer named Capillary Biomedical has acquired by Tandem Diabetes. In the infusion business segment, it has expanded the product portfolio of Tandem Diabetes.
• In March 2022- For the wireless Agilia Connect Infusion System, Fresenius Kabi received USFDA approval. The system includes the Agilia Syringe Pump and the Agilia Volumetric Pump with Vigilant Software Suite-Vigilant Master Med technology.

Report Scope